Diego Antonio Pereira-Martins
Overview
Explore the profile of Diego Antonio Pereira-Martins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
60
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Santos de Macedo B, Albuquerque de Melo M, Pereira-Martins D, Machado-Neto J, Traina F
Biochim Biophys Acta Rev Cancer
. 2024 Nov;
1879(6):189214.
PMID: 39515545
The gradual acquisition of genetic and epigenetic disturbances bestows malignant traits upon hematopoietic stem cells, subverting them into a founder and reservoir cell for de novo acute myeloid leukemia (AML)...
2.
Santos de Macedo B, Albuquerque de Melo M, Pereira-Martins D, Machado-Neto J, Traina F
Sci Rep
. 2024 Oct;
14(1):23882.
PMID: 39396074
Beyond its clinical diversity and severity, acute myeloid leukemia (AML) is known for its complex molecular background and for rewiring biological processes to aid disease onset and maintenance. FLT3 mutations...
3.
Lima K, Nogueira F, Cipelli M, Carvalho M, Pereira-Martins D, Silva W, et al.
Eur J Pharmacol
. 2024 Jun;
977:176723.
PMID: 38851560
Acute lymphoblastic leukemia (ALL), a complex malignancy, displays varying expression profiles of PIP4K2-related genes in adult patients. While PIP4K2A expression is elevated in ALL bone marrow cells compared to healthy...
4.
Rojas C, Pereira-Martins D, Bellido More C, Sternadt D, Weinhauser I, Hilberink J, et al.
Br J Haematol
. 2024 Apr;
204(6):2287-2300.
PMID: 38651345
Despite advancements in utilizing genetic markers to enhance acute myeloid leukaemia (AML) outcome prediction, significant disease heterogeneity persists, hindering clinical management. To refine survival predictions, we assessed the transcriptome of...
5.
Lima K, Carvalho M, Pereira-Martins D, Nogueira F, de Miranda L, do Nascimento M, et al.
Int J Mol Sci
. 2023 Dec;
24(23).
PMID: 38069220
Phosphatidylinositol-5-phosphate 4-kinase type 2 (PIP4K2) protein family members (PIP4K2A, PIP4K2B, and PIP4K2C) participate in the generation of PIP,P, which acts as a secondary messenger in signal transduction, a substrate for...
6.
Cunningham A, Oudejans L, Geugien M, Pereira-Martins D, Wierenga A, Erdem A, et al.
Blood Adv
. 2023 Oct;
8(1):56-69.
PMID: 37906522
Cysteine is a nonessential amino acid required for protein synthesis, the generation of the antioxidant glutathione, and for synthesizing the nonproteinogenic amino acid taurine. Here, we highlight the broad sensitivity...
7.
Lima K, Pereira-Martins D, de Miranda L, Coelho-Silva J, da Silva Leandro G, Weinhauser I, et al.
Blood Cancer J
. 2022 Nov;
12(11):151.
PMID: 36347832
The treatment of acute leukemia is challenging because of the genetic heterogeneity between and within patients. Leukemic stem cells (LSCs) are relatively drug-resistant and frequently relapse. Their plasticity and capacity...
8.
Fernandes de Oliveira Costa A, Marani L, Bianco T, Queiroz Arantes A, Aparecida Lopes I, Pereira-Martins D, et al.
Front Immunol
. 2022 Oct;
13:768592.
PMID: 36211444
In cancer, tumor cells and their neoplastic microenvironment can sculpt the immunogenic phenotype of a developing tumor. In this context, natural killer (NK) cells are subtypes of lymphocytes of the...
9.
Cunningham A, Erdem A, Alshamleh I, Geugien M, Pruis M, Pereira-Martins D, et al.
Blood
. 2022 Aug;
140(19):2037-2052.
PMID: 35984907
Targeting altered tumor cell metabolism might provide an attractive opportunity for patients with acute myeloid leukemia (AML). An amino acid dropout screen on primary leukemic stem cells and progenitor populations...
10.
Alves-Silva A, Fenerich B, Fonseca N, Fernandes J, Coelho-Silva J, Pereira-Martins D, et al.
Invest New Drugs
. 2022 Jan;
40(3):576-585.
PMID: 35015172
Background: Myeloproliferative neoplasms (MPN) are disorders characterized by an alteration at the hematopoietic stem cell (HSC) level, where the JAK2 mutation is the most common genetic alteration found in classic...